Related Experiment Video
Updated: Sep 21, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC
Chunyan Liu1,2, Shan Zhu1,3, Jing Wu1,3
1Laboratory for Tumor Immunology, The First Hospital of Jilin University, Changchun, Jilin 130061, China.
Abstract:
Non-small cell lung cancer (NSCLC) is characterized by intricate genetic modifications and mechanisms that allow it to evade immune detection, which complicates the pursuit of lasting therapeutic responses. The effectiveness of treatments is greatly affected by the interaction between tumor genetic profiles and the surrounding immune microenvironment, highlighting the need for carefully designed therapeutic combinations. This review provides a comprehensive analysis of oncogenic drivers and signaling pathways (such as the KRAS, BRAF, and CD73/adenosine pathway) that interact with immune checkpoint inhibitors (ICIs), offering practical insights for personalized treatment approaches. The key findings focus on the use of biomarkers to guide the selection of immunotherapy or ICI-based combination therapies (e.g., ICIs plus tyrosine kinase inhibitors or signaling pathway inhibitors). We emphasize the importance of integrating tumor genomics with immune profiling to improve patient survival outcomes. This review aims to optimize treatment strategies by synthesizing insights from recent clinical trials and preclinical research, ultimately improving therapeutic efficacy in NSCLC.
Related Concept Videos
Tumor Immunotherapy
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...